期刊文献+

光学相干断层成像在眼科视网膜黄斑部体检中的应用 被引量:9

The application of optical coherence tomography( OCT) in retinal macula examination
下载PDF
导出
摘要 目的:观察光学相干断层成像( optical coherence tomography,OCT)在眼科体检中对视网膜黄斑部疾病检出的应用价值。方法收集在某院健康体检中,自愿应用OCT在眼视网膜黄斑部检查者8302人,其中男5216人,女3086人,年龄23~72岁。视力0.05~1.5。分析OCT在体检人群眼黄斑部病变的早期筛查的作用。结果 OCT体检8302人,检出视网膜黄斑部病变1743人,检出率21.0%。视力0.05~0.3890人,检出880人,检出率98.9%;0.4~0.82153人,检出686人,检出率31.9%;>0.85259人,检出177人,检出率3.4%。20~39岁1586人,检出105人,检出率6.6%;40~60岁5552人,检出926人,检出率16.7%;>60岁1164人,检出712人,检出率61.2%。结论应用OCT对眼底黄斑部检查,其病变的检出率高,并与受检者年龄和视力呈一定的关系。在健康体检中能早期发现眼底黄斑部病变,是防盲治盲中不可缺少检测手段。 Objective To study the significance of optical coherence tomography OCT in retinal macule examination.Meth-ods Collecting data from people who were willing to have OCT examination in retinal macula, during their health examination in the hospital.Results Among 8302 volunteers, 5216 were male, 3086 were female.The age was from 23 to 72.Vison acuity ranged from 0.05-1.5.Analysing the significance of OCT in early period screening, 8302 volunteers were examined, 1743 of whom were diag-nosed of macular diseases.The positive rate was 21.0%.Vision acuity ranges from 0.05 to 0.3, 890 were examined and the positive rate was 98.9%(880).0.4-0.8, 2153 were examined and the positive rate was 31.9%(686);0.8, 5259 were examined and the positive rate was 3.4%(177).Among 1586 volunteers whose age range from 20 to 39, the positive rate was 6.6%(105).Among 5552 volunteers whose age were from 40 to 60, the positive rate was 16.7%(926).1164 volunteers were at 60, whose positive rate was 61.2%(712).Conclusion OCT has significant effect on examining retinal macular diseases, the positive rate is proportional to age and conversely proportional to vision acuity.It is helpful for diagnosing macular diseases timely in health examination, which plays a vital role in preventing blindness.
出处 《东南国防医药》 2015年第4期356-357,401,共3页 Military Medical Journal of Southeast China
基金 中国健康促进基金会(chpf2014-oct-01)
关键词 光学相干断层成像 体检 视网膜 黄斑部病变 作用 optical coherence tomography health examination retina macular diseases effect
  • 相关文献

参考文献11

二级参考文献47

  • 1王兵.图像数据库的研究[J].河北大学学报:自然科学版,1998,12. 被引量:7
  • 2Gass JDM.Stereoscopic atlas of macular disease; diagnosis and treatment[M] ,ed 4,St.Louis,CV Mosby,1997:304-306. 被引量:1
  • 3Rosenthal R,Bakall B,Kinnick T,et al.Expression of bestrophin-1,the product of the VMD2 gene,modulates voltage-dependent Ca^2+ channels in retinal pigment epithelial cells[J].FASEB J,2006,20:178-180. 被引量:1
  • 4Gomez A,Cedano J,Oliva B,et al.The gene causing the Best's macular dystrophy (BMD) encodes a putative ion exchanger[J].DNA seq,2001,12:431-435. 被引量:1
  • 5Eksandh L,Bakall B,Bauer B,et al.Best's vitelliform macular dystrophy caused by a new mutation (Val89Ala) in the VMD2 gene[J].Ophthalmic Genet,2001,22:107-115. 被引量:1
  • 6Marchant D,Gogat K,Dureau P,et al.Use of denaturing HPLC and automated sequencing to screen the VMD2 gene for mutations associated with Best's vitelliform macular dystrophy[J].Ophthalmic Genet,2002,23:167-174. 被引量:1
  • 7O'Gorman S,Flaherty WA,Fishman GA,et al.Histopathologic findings in Best's vitelliform macular dystrophy[J].Arch Ophthalmol,1988,106:1261-1268. 被引量:1
  • 8Weingeist TA,Kobrin JL,Watzke RC.Histopathology of Best's macular dystrophy[J].Arch Ophthalmol,1982,100:1108-1114. 被引量:1
  • 9Frangieh GT,Green WR,Fine SL.A histopathologic study of Best's macular dystrophy[J].Arch Ophthalmol,1982,100:1115-1121. 被引量:1
  • 10Miller SA.Multifocal Best' s vitelliform dystrophy[J].Arch Ophthalmol,1977,95:984-990. 被引量:1

共引文献102

同被引文献69

  • 1关新辉,张翌韦,梁勇.浅谈应用OCT早期诊断青光眼的临床价值[J].当代医药论丛,2014,12(13):61-61. 被引量:4
  • 2Realini T, Nguyen QH, Katz G, et al. Fixed-combination brinzo- lamide l%/brimonidine 0.2%vs monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hyper- tension : Results of a pooled analysis of two phase 3 studies [ J ]. Eye, 2013, 27(7): 121-126. 被引量:1
  • 3Motolko MA. Comparison of allergy rates in glaucoma patients re- ceiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy [J]. Curr Med Res Opin, 2008, 24(9): 89-95. 被引量:1
  • 4Baiza D, Lamas LM, Ayala JF. Comparison of timolol 0.5% + bri- monidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimoni- dine 0.2% in a Mexican population with primary open-angle glau- coma or ocular hypertension [ J]. Clin Ophthalmol, 2012, 21 (5) :129-134. 被引量:1
  • 5Javitt JC, Schiffman RM. Clinical success and quality of life with bfimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular t hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group ! [ J ]. J Glaucoma, 2000, 9(3) :261-269. 被引量:1
  • 6Whitson JT, Realini TN, Nguyen QH, et al. Six-month results from a Phase III randomized trial of fixed-combination brinzolamide 1% + brimonidine 0.2% versus brinzolamide or brimonidine mono- therapy in glaucoma or ocular hypertension [ J ]. Clin Ophthalmol, 2013, 11(8) :135-141. 被引量:1
  • 7Konstas AG, Quaranta L, Yan DB, et al. Twenty-four hour efficacy with the dorzolamide/timolol-fixed combination compared with the brimonidine/timolol-fixed combination in primary open- angle glaucoma [ J]. Eye, 2012, 26( 1 ) : 189-193. 被引量:1
  • 8Krupin T, Liebmann JM, Greenfield DS, et al. Gardiner SA ran- domized trial of brimonidine versus timolol in preserving visual function : results from the Low-Pressure Glaucoma Treatment Study [J]. Am J Ophthalmol, 2011, 151(4) :247-251. 被引量:1
  • 9Spaeth GL, Bernstein P, Caprioli J, et al. Control of intraocular pressure and fluctuation with fixed-combination brimonidine- timolol versus brimonidine or timolol monotherapy [ J]. AmJ Oph- thalmol, 2011, 151(2) :297-302. 被引量:1
  • 10Konstas AG, Hol16 G, Haidich AB, et al. Comparison of 24-hour intraocular pressure reduction obtained with brinzolamide/timolol or brimonidine/timolol fixed-combination adjunctive to travoprosttherapy [J]. J Ocul Pharmacol Ther, 2013, 29(7) :129-134. 被引量:1

引证文献9

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部